943119-08-2Relevant articles and documents
Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening
Disch, Jeremy S.,Duffy, Jennifer M.,Lee, Esther C. Y.,Gikunju, Diana,Chan, Betty,Levin, Benjamin,Monteiro, Michael I.,Talcott, Sarah A.,Lau, Anthony C.,Zhou, Fei,Kozhushnyan, Anton,Westlund, Neil E.,Mullins, Patrick B.,Yu, Yan,Von Rechenberg, Moritz,Zhang, Junyi,Arnautova, Yelena A.,Liu, Yanbin,Zhang, Ying,McRiner, Andrew J.,Keefe, Anthony D.,Kohlmann, Anna,Clark, Matthew A.,Cuozzo, John W.,Huguet, Christelle,Arora, Shilpi
, p. 5049 - 5066 (2021)
Bispecific degraders (PROTACs) of ERα are expected to be advantageous over current inhibitors of ERα signaling (aromatase inhibitors/SERMs/SERDs) used to treat ER+ breast cancer. Information from DNA-encoded chemical library (DECL) screening provides a me
Palladium(II)-Catalyzed C(sp2)-H Bond Activation/C-N Bond Cleavage Annulation of N-Methoxy Amides and Arynes
Cheng, Xiu-Fen,Yu, Ting,Liu, Yi,Wang, Nan,Chen, Zhenzhen,Zhang, Guang-Lu,Tong, Lili,Tang, Bo
, p. 2087 - 2092 (2022/04/07)
The Pd(II)-catalyzed C-H bond activation/C-N bond cleavage annulation reaction of N-alkyoxyamide aryne is developed to synthesize 9,10-dihydrophenanthrenone derivatives. This reaction exhibited good functional group compatibility with yields up to 92%. Detailed mechanistic studies showed that the key to C-N bond cleavage is the formed eight-membered palladacycle intermediate undergoing nucleophilic addition to the carbonyl group, which provides a new and practical way for N-alkoxyamide directed C-H bond activation.
GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF
-
Page 58, (2010/02/05)
1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.
